Key Points
- Organogenesis director Arthur Leibowitz purchased 5,000 shares on March 9 at an average price of $2.68 (total $13,400), increasing his direct ownership to 291,014 shares — a 1.75% boost; the transaction was disclosed in an SEC Form 4.
- Strong recent results but low share price: the company beat quarterly estimates (EPS $0.31 vs $0.21; revenue $225.6M vs $172.7M) and carries an average analyst target of $8.50/"Moderate Buy", yet the stock trades around $2.62 (near its 12‑month low) with a $337M market cap.
Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz bought 5,000 shares of the firm's stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $2.68 per share, with a total value of $13,400.00. Following the purchase, the director directly owned 291,014 shares of the company's stock, valued at $779,917.52. This trade represents a 1.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Organogenesis Trading Down 1.1%
ORGO traded down $0.03 during trading on Friday, hitting $2.62. The company's stock had a trading volume of 336,287 shares, compared to its average volume of 737,955. The firm has a market capitalization of $337.04 million, a P/E ratio of 32.75 and a beta of 1.43. Organogenesis has a twelve month low of $2.61 and a twelve month high of $7.08. The stock's fifty day moving average price is $3.74 and its 200-day moving average price is $4.47. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04.
Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.21 by $0.10. The company had revenue of $225.61 million during the quarter, compared to the consensus estimate of $172.68 million. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. Analysts anticipate that Organogenesis will post -0.07 EPS for the current year.
Hedge Funds Weigh In On Organogenesis
Several large investors have recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its holdings in Organogenesis by 69.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company's stock worth $20,488,000 after purchasing an additional 1,997,038 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Organogenesis by 3.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company's stock valued at $8,862,000 after buying an additional 91,118 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in shares of Organogenesis during the second quarter valued at about $63,000. Jump Financial LLC purchased a new stake in shares of Organogenesis in the fourth quarter worth about $66,000. Finally, BNP Paribas Financial Markets grew its stake in Organogenesis by 57.0% during the third quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company's stock valued at $61,000 after acquiring an additional 5,273 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the company. BTIG Research cut their price target on Organogenesis from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, February 27th. Wall Street Zen raised Organogenesis from a "hold" rating to a "buy" rating in a research report on Sunday, March 8th. Finally, Weiss Ratings raised Organogenesis from a "sell (d+)" rating to a "hold (c)" rating in a research report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $8.50.
Check Out Our Latest Report on Organogenesis
About Organogenesis
(
Get Free Report)
Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.
Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
